Screener
Vertex Pharmaceuticals VRTX Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000875320-26-000173
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 7,122.5 | 6,977.2 |
| Commitments and contingencies (Note L) | ||
| Shareholders’ equity: | ||
| Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued | — | — |
| Common stock, $0.01 par value; 500,000,000 shares authorized, 254,163,953 and 253,991,224 shares issued and outstanding, respectively | 2.5 | 2.5 |
| Additional paid-in capital | 4,743.2 | 5,119.2 |
| Accumulated other comprehensive income (loss) | 24.8 | (15.9) |
| Retained earnings | 14,591.4 | 13,560.0 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vertex Pharmaceuticals's preferred stock, shares authorized?
- Vertex Pharmaceuticals (VRTX) reported preferred stock, shares authorized of 1M in Q1 2026.
- How has Vertex Pharmaceuticals's preferred stock, shares authorized changed year-over-year?
- Vertex Pharmaceuticals's preferred stock, shares authorized decreased by 0.0% year-over-year, from 1M to 1M.
- What is the long-term trend for Vertex Pharmaceuticals's preferred stock, shares authorized?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from 1M to 1M.
Ask your AI about Vertex Pharmaceuticals's preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude